title: [Clinical and immunological studies of the therapeutical effect of cytokines combined with 5-fluorouracil in metastatic kidney cancer].
abstract: The authors present the results of a six-year clinicoimmunological study of a therapeutic effect of cytkins combined with 5-fluoruracyl in metastatic renal-cell carcinoma. Two therapeutic regiments have been used: rhIFN-a + 5-FU and rhIL-2 + RHifn-A + 5-FU. In cytokin-sensitive patients, both therapy protocols vrs conventional therapeutic alternatives (cytostatics, hormones, irradiation) have been shown to increase the frequency of achievement of remission by objective scoring and life span of the patients. There was an improvement in patients on having received the complex with IL-2 but a higher therapeutic effect appeared to be accompanied by substantial side effects. Recommendatory measures well-targeted to those patients with metastatic renal-cell carcinoma who are to be placed on cytokinotherapy are presented together with immunological indices to monitor the treatments administered and prognosis.
authors.forename: A F
authors.initials: AF
authors.lastname: Vozianov
authors.forename: K P
authors.initials: KP
authors.lastname: Zak
authors.forename: V I
authors.initials: VI
authors.lastname: Zubko
authors.forename: A M
authors.initials: AM
authors.lastname: Romanenko
authors.forename: I A
authors.initials: IA
authors.lastname: Klimenko
authors.forename: V M
authors.initials: VM
authors.lastname: Babich
authors.forename: Iu I
authors.initials: IuI
authors.lastname: Kushneruk
authors.forename: A Iu
authors.initials: AIu
authors.lastname: Shcherbak
authors.forename: S V
authors.initials: SV
authors.lastname: Bazalitskaia
authors.forename: M A
authors.initials: MA
authors.lastname: Gruzov
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018572:Disease-Free Survival; D004357:Drug Synergism; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007376:Interleukin-2 / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D007958:Leukocyte Count; D007962:Leukocytes / Q000166:cytology / Q000276:immunology* / Q000648:ultrastructure; D018655:Lymphocyte Count; D008214:Lymphocytes / Q000166:cytology / Q000276:immunology / Q000648:ultrastructure; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins; D012074:Remission Induction
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007376:Interleukin-2; D011994:Recombinant Proteins; D005472:Fluorouracil